Pyoderma gangrenosum—a novel approach?;Pyoderma gangraenosum – ein neuer Ansatz?

Wiener Medizinische Wochenschrift

Volumn 167, Issue 3-4, 2017, Pages 58-65

  Chokoeva, Anastasia Atanasova ^a   Cardoso, José Carlos ^b   Wollina, Uwe ^c   Tchernev, Georgi ^a  

^a Onkoderma Policlinic for Dermatology and Dermatologic Surgery   (Bulgaria)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

Author keywords

Biological agents; Etiopathogenesis; Neutrophilic disorders; Pyoderma gangrenosum; Treatment

Indexed keywords

ANAKINRA; BIOLOGICAL PRODUCT; CANAKINUMAB; INFLAMMASOME; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; AUTACOID; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN-1BETA-CONVERTING ENZYME INHIBITOR; PROTEIN KINASE INHIBITOR; SERINE PROTEINASE INHIBITOR; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR; VIRAL PROTEIN;

BIOLOGICAL ACTIVITY; INFLAMMATION; MONOTHERAPY; PATHOGENESIS; PYODERMA GANGRENOSUM; REVIEW; ANTAGONISTS AND INHIBITORS; BLOOD; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; IMMUNOLOGY;

DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; INFLAMMASOMES; INFLAMMATION MEDIATORS; PROTEIN KINASE INHIBITORS; PYODERMA GANGRENOSUM; RECEPTORS, INTERLEUKIN-1; SERPINS; TUMOR NECROSIS FACTOR-ALPHA; VIRAL PROTEINS;

EID: 84977117311     PISSN: 00435341     EISSN: 1563258X     Source Type: Journal    
DOI: 10.1007/s10354-016-0472-z     Document Type: Review

References (38)

1. Cozzani E, Gasparini G, Parodi A. Pyoderma gangrenosum: a systematic review. G Ital Dermatol Venereol. 2014;149(5):587–600.
2. Wollina U, Tchernev G. Pyoderma gangrenosum: pathogenetic oriented treatment approaches. Wien Med Wochenschr. 2014;164:263.
3. Gameiro А, Pereira N, Cardoso JC, Margarida Gonçalo M. Pyoderma gangrenosum: challenges and solutions. Clin Cosmet Investig Dermatol. 2015;8:285–93.
4. Argüelles-Arias F, Castro-Laria L, Lobatón T, Aguas-Peris M, Rojas-Feria M, Barreiro-de Acosta M, Soto-Escribano P, Calvo-Moya M, Ginard-Vicens D, Chaparro-Sánchez M, Hernández-Durán M, Castro-Senosiain B, Fernández-Villaverde A, García-Sánchez V, Domínguez-Muñoz E, Caunedo-Álvarez A, Herrerías-Gutiérrez JM. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci. 2013;58(10):2949–54.
5. Beer HD, Contassot E, French LE. The inflammasomes in autoinflammatory diseases with skin involvement. J Invest Dermatol. 2014;134(7):1805–10.
6. Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol. 2002;3:149–58.
7. Lipsker D, Lenormand C. Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases. Ann Dermatol Venereol. 2012;139(6–7):459–67.
8. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka TJ. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) – a new autoinflammatory syndrome distinct from PAPA syndrome. Am Acad Dermatol. 2012;66(3):409–15.
9. Charles A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720–32.
10. Lukens JR, Kanneganti TD. SHP-1 and IL-1α conspire to provoke neutrophilic dermatoses. Rare Dis. 2014;2:e27742.
11. Dinarello CA, Meer JW van der. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;pii: S1044-5323(13):00089–00084.
12. Doherty TA, Brydges SD, Hoffman HM. Autoinflammation: translating mechanism to therapy. J Leukoc Biol. 2011;90(1):37–47.
13. Jaeger T, Andres C, Grosber M, Zirbs M, Hein R, Ring J, Traidl-Hoffmann C. Pyoderma gangrenosum and concomitant hidradenitis suppurativa – rapid response to canakinumab (anti-IL-1b). Eur J Dermatol. 2013;23(3):408–10.
14. Church LD, Cook GP. Michael F McDermott. Primer: inflammasomes and interleukin 1 bold beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4:34–42.
15. Arend WP. The mode of action of cytokine inhibitors. J Rheumatol Suppl. 2002;65:16–21.
16. Dinarello CA, Simon A, Meer JWM van der. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633–52.
17. Oka M, Berking C, Nesbit M, Satyamoorthy K, Schaider H, Murphy G, Ichihashi M, Sauter E, Herlyn M. Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest. 2000;80(4):595–604.
18. Rallis E, Koumantaki-Mathioudaki E, Tsiatoura A, Stavropoulos P, Katsambas A. Pyoderma gangrenosum and tumor necrosis factor α agents. Cutis. 2013;92(4):E1–2.
19. Callus BA, Vaux DL. Caspase inhibitors: viral, cellular and chemical. Cell Death Differ. 2007;14:73–8.
20. Zippi M, Pica R, De Nitto D, Paoluzi P. Biological therapy for dermatological manifestations of inflammatory bowel disease. World J Clin Cases. 2013;1(2):74–8.
21. Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, Greebe RJ. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J Dermatolog Treat. 2011;22:261–5.
22. Tchernev G, Trebing D, Göring H‑D, Steinhoff M, Zouboulis CC, Orfanos C. Pyoderma gangrenosum in Crohn’s disease – the role of immunologic parameters and histological data in diagnosis and differential diagnosis. Bulg J Hepatogastroenterol. 2005;7:56–60.
23. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol. 2001;137:930–3.
24. Teich N, Klugmann T. Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis. J Crohns Colitis. 2014;8(1):85–6.
25. Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-α therapies. J Cutan Med Surg. 2005;9(6):296–302.
26. Vitale A, Rigante D, Lucherini OM, Caso F, Muscari I, Magnotti F, Brizi MG, Guerrini S, Patti M, Punzi L, Galeazzi M, Cantarini L. Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediat Inflamm. 2013;2013:939847.
27. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1–14.
28. Chen TL, Chang CC, Lin YL, Ueng YF, Chen RM. Signal-transducing mechanisms of ketamine-caused inhibition of interleukin-1 beta gene expression in lipopolysaccharide-stimulated murine macrophage-like Raw 264.7 cells. Toxicol Appl Pharmacol. 2009;240(1):15–25.
29. Wu GJ, Chen TL, Ueng YF, Chen RM. Ketamine inhibits tumor necrosis factor-alpha and interleukin-6 gene expressions in lipopolysaccharide-stimulated macrophages through suppression of toll-like receptor 4‑mediated c‑Jun N‑terminal kinase phosphorylation and activator protein-1 activation. Toxicol Appl Pharmacol. 2008;228(1):105–13.
30. Pazyar N, Feily A, Yaghoobi R. An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. Curr Clin Pharmacol. 2012;7(4):271–5.
31. Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161(5):1199–201.
32. Geusau A, Mothes-Luksch N, Nahavandi H, Pickl WF, Wise CA, Pourpak Z, Ponweiser E, Eckhart L, Sunder-Plassmann R. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol. 2013;149(2):209–15.
33. Gönül M, Cevirgen Cemil B, Keseroglu HO, Kaya Akis H. New Described Dermatological Disorders. Biomed Res Int. 2014;2014:616973.
34. Bruzzese V. Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor α therapy. J Clin Rheumatol. 2012;18(8):413–5.
35. Powell FC, O’Kane M. Management of pyoderma gangrenosum. Dermatol Clin. 2002;20:347–55.
36. Wollina U. Pyoderma gangrenosum – a review. Orphanet J Rare Dis. 2007;2:19.
37. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: Classification and management. J Am Acad Dermatol. 1996;34:395–409.
38. Goodarzi H, Sivamani RK, Garcia MS, Wehrli LN, Craven H, Ono Y, Maverakis E. Effective Strategies for the Management of Pyoderma Gangrenosum. Adv Wound Care (New Rochelle). 2012;1(5):194–9.